The endogenous cannabinoid system in Individuals with opioid use disorder and healthy: A brain imaging study
- Study HIC#:2000033525
- Last Updated:02/21/2025
The purpose of the study is to examine the endocannabinoid (eCB) function in individuals with Opioid Use Disorder (OUD) who take methadone or suboxone by measuring cannabinoid receptor 1 (CB1R) availability. Participation includes a screening visit, brain imaging sessions including MRI and PET scan, and two follow-up phone calls. Total estimated compensation is up to $550.
Contact Us
For more information about this study, including how to volunteer, contact:
Angelina Contreras
- Phone Number: 1-203-974-7324
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
- Key Inclusion Criteria
- Men and women aged 18 years and older.
- DSM-5 diagnosis of opioid use disorder (OUD group).
- Physically healthy, i.e., with no clinically unstable medical conditions.
- Have arterial access sufficient to allow blood sampling as per protocol.
- Key Exclusion Criteria
- Any current major medical disease that may be a risk factor for conducting PET scans, at the discretion of the PI.
- Current or past diagnosis of major psychiatric disorders such as psychosis, bipolar disorder, and post-traumatic stress disorder, at the discretion of the PI.
- Women with a positive pregnancy test or women who are lactating.
- Claustrophobia.
- History of a bleeding disorder or current use of anticoagulants.
